A transaminase mutant and its application
By performing amino acid mutation on amino acids on amino acid ATA55, a transaminase mutant with universality and high enzyme activity was obtained, which solved the problem of inhibition of enzymes by alcohol solvents and achieved the flexibility and economicality of organic solvents in sitagliptin production. Improvement solves the problems of expensive DMSO and complex post-processing.
Patent Information
- Application Number
- CN202111516721.4
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2021-12-07
- Publication Date
- 2024-11-22
- Estimated Expiration
- 2041-12-07
AI Technical Summary
The existing aminotransferase ATA55 has an inhibitory effect on alcohol solvents, resulting in a significant reduction in the rate of enzyme catalytic reaction, which limits the optimization of sitagliptin production process, especially when seeking alternatives to cheap organic solvents due to the high cost of DMSO and complex post-processing. Encounter difficulties.
: : : : : : : : : : : : : : : Solvent.
It realizes high enzyme activity in different organic solvents, reduces the raw material cost in sitagliptin production, improves the economics of the enzyme synthesis process, and avoids the inhibitory effect of alcohol solvents on enzymes, enhancing the process Flexibility and efficiency.
Smart Images

Figure BDA0003397065020000011 
Figure BDA0003397065020000021 
Figure BDA0003397065020000071
Abstract
Description
Technical Field
[0001] The invention belongs to the technical field of enzyme catalysis, and in particular relates to a transaminase mutant and use thereof in producing sitagliptin. Background Art
[0002] The chemical name of sitagliptin is 7-[(3R)-3-amino-1-oxo-4-(2,4,5-trifluorophenyl)butyl]-5,6,7,8-tetrahydro-3-trifluoromethyl-1,2,4-triazolo[4,3-a]pyrazine. Its phosphate monohydrate is the first dipeptidyl peptidase-4 (DPP-4) inhibitor drug used for the treatment of type 2 diabetes. It can improve blood sugar control by increasing the level of active incretin hormone and has the advantages of low incidence of adverse reactions and good safety.
[0003] The key step in the synthesis of sitagliptin is the synthesis of chiral amino groups, and there are currently two methods for industrial production. Patent WO2004085378A1 uses asymmetric hydrogenation of enamines with a chiral rhodium catalyst to construct a chiral center, which has the advantages of short synthesis steps, simple route, high substrate conversion rate and product optical purity. Patent CN102405281A is based on Arthrobacter sp. (R) -ω-transaminase as the research object. By combining strategies such as site-directed saturation mutagenesis, full gene random mutagenesis and protein structure computer-aided design, a new type of transaminase that can efficiently catalyze (2Z)-4-oxo-4-[3-(trifluoromethyl)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazine-7-(8H)-yl]-1-(2,4,5-trifluorophenyl) butan-2-one to synthesize sitagliptin in a 50% water-50% DMSO mixed liquid phase is finally obtained. Compared with chemical synthesis, the enzymatic conversion strategy can increase the product yield by 10-13%, increase production efficiency by 53%, reduce total waste emissions by 19%, and no heavy metals need to be added during the reaction. Currently, the bioenzymatic method has become the preferred option for synthesizing chiral pharmaceutical chemicals or chemical intermediates.
[0004]
[0005]
[0006] The applicant reported a transaminase mutant ATA55 in patent document 202111141071X, whose amino acid sequence is SEQ ID NO.1 in this application, which has high enzyme activity and can efficiently catalyze the reaction of substrate (2Z)-4-oxo-4-[3-(trifluoromethyl)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazine-7-(8H)-yl]-1-(2,4,5-trifluorophenyl)butan-2-one (Compound I) to generate the target product sitagliptin (Compound II). In the process of optimizing the production process for further commercial application, it was found that it has selectivity / preference for organic solvents as cosolvents in the reaction system, and it seems to be only suitable for water-DMSO mixed solution reaction system. Considering that DMSO is expensive and post-processing is complicated, in order to reduce production costs, especially raw material costs, we try to use cheap bulk organic solvents such as methanol, ethanol, propanol, isopropanol, etc. instead of DMSO. However, experiments have found that these alcohol solvents have an inhibitory effect on the transaminase ATA55, significantly reducing the rate of the enzyme-catalyzed reaction, posing a technical obstacle to process optimization. Summary of the invention
[0007] In order to break through the bottleneck of organic solvent types limiting the process optimization of transaminase ATA55 for catalytic preparation of sitagliptin and reduce the production cost of sitagliptin, considering that transaminase is a protein with certain dielectric properties, different organic solvents have different effects on the conformation and conformational stability of the same protein. We focus our work on the transformation of transaminase ATA55 itself, including enzyme immobilization, chemical modification of enzymes, and amino acid mutations. A breakthrough has been made in amino acid mutations, and a mutant enzyme with universality, i.e., low selectivity to organic cosolvents and higher enzyme activity than transaminase ATA55 has been obtained. Therefore, the technical solution of the present invention is as follows:
[0008] A transaminase mutant, whose amino acid sequence is SEQ ID NO:3:
[0009] MAKSADTPSNMYTHDTGLDYIKFSEYEGSADNNLNGGAAWIEGAFVPPSEARISVFDQGFYTSDATYTTFSVWHGNAFRLDDHIERLYSNAESMRLIPPLTQDEVKEIALELVAKTELRDAMVTVTFTRGLSSTPFERDITNHRPQVYMTAIPYVSIVPFDRIRNGV HAMVAQSVRRTPRSSIDPQVKNFQWGDLIRAIQETNDRGFELPVLLDCDGLLAEGPGFNVVVIKDGVVRSPGRAALPGITRKTVLEIAESLGHEAILADISLADLYDADEVLGCSTGGGVWPFVSVDGNPISDGVPGPVTQSIIRRYWELNVEPSQLLTPVQY(SEQ ID NO:3).
[0010] The present invention also provides a gene encoding the above aminotransferase mutant.
[0011] In a preferred embodiment, the nucleotide sequence of the above gene may be SEQ ID NO:4.
[0012] Another aspect of the present invention provides a plasmid comprising the above gene. The plasmid comprises a vector for expressing the above gene, such as SEQ ID NO: 4, preferably a vector of the PET series, such as pET22b, pET24a, pET28a, etc., but is not limited thereto.
[0013] Another aspect of the present invention provides a microorganism for expressing the above-mentioned aminotransferase mutant SEQ ID NO: 3, for example, a microorganism transformed with the above-mentioned plasmid.
[0014] Preferably, the microorganism is selected from Bacillus subtilis, Corynebacterium glutamicum, Pichia pastoris, Saccharomyces cerevisiae, and Escherichia coli, and more preferably, the microorganism is Escherichia coli BL21 (DE3).
[0015] Another aspect of the present invention provides use of the above-mentioned aminotransferase mutant SEQ ID NO: 3 or a microorganism expressing the same in the production of sitagliptin.
[0016] Specifically, in the production of sitagliptin, the sitagliptin precursor ketone ((2Z)-4-oxo-4-[3-(trifluoromethyl)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazine-7-(8H)-yl]-1-(2,4,5-trifluorophenyl)butan-2-one) is used as a substrate raw material, and the above-mentioned transaminase mutant SEQ ID NO:3 or a microorganism expressing the same is used as a catalyst to catalyze the 2-position amination reaction to obtain the target product sitagliptin.
[0017] Preferably, the reaction system contains pyridoxal phosphate as a coenzyme.
[0018] The above reaction system may further comprise o-phenylenediamine dihydrochloride, or isopropylamine and / or triethanolamine as an amino group donor.
[0019] Since the above transaminase mutant has high thermal stability, the enzyme reaction temperature during the catalytic production of sitagliptin can be 40-50°C, preferably around 45°C.
[0020] The pH value of the reaction system is 8.0-9.0, preferably 8.5.
[0021] In order to speed up the reaction, an organic solvent may be added to the reaction system as a co-solvent for the substrate, and the organic solvent includes but is not limited to DMSO, methanol, ethanol, propanol, isopropanol, or a mixture of two or more thereof.
[0022] When the co-solvent is methanol, the concentration of methanol in the reaction system is 10%-60%, preferably 50%.
[0023] Further, the substrate concentration may be 2-100 g / L, preferably 100 g / L.
[0024] The present invention uses solvent methanol as the environmental screening pressure, combines with genetic engineering mutation technology, and conducts multiple rounds of mutations on the transaminase mutant ATA55 (amino acid sequence is SEQ ID NO: 1, and the nucleotide sequence of its encoding gene is SEQ ID NO: 2) reported in patent document 202111141071X. A mutant SEQ ID NO: 3 with low organic solvent inhibition and higher enzyme activity is screened out, which lays the foundation for the optimization of the reaction system of the sitagliptin production process and improves the economy of the process route of enzymatic synthesis of sitagliptin. DETAILED DESCRIPTION
[0025] The present invention is completed on the basis of patent document 202111141071X, so part of the contents of the patent document, including detection methods, strain culture and fermentation conditions, are introduced into this article as a reference.
[0026] In order to screen a mutant with low selectivity for organic solvents, i.e., low solvent inhibition, and an enzyme activity at least not lower than that of transaminase ATA55 (amino acid sequence of SEQ ID NO: 1), the present invention uses transaminase ATA55 as the initial enzyme to continue mutation, and performs the mutation by applying environmental pressure. The amino acid sequence of the initial enzyme is SEQ ID NO: 1:
[0027] MAKSADTPSNMYTHDTGLDYIKFSEYEGSADNNLAGGAAWIEGAFVPPSEARISVFDQGFYTSDATYTTFSVWHGNAFRLDDHIERLYSNAESMRLIPPLTQDEVKEIALELVAKTELREAMVTVTFTRGLSSTPFERDITNHRPQVYMTAVPYQTIVPFDRIRNGV HAMVAQSVRRTPRSSIDPQVKNFQWGDLIRAIQETNDRGFELPVLLDCDGLLAEGPGFNVVVIKDGVVRSPGRAALPGITRKTVLEIAESLGHEAILADISLADLYDADEVLGCSTGGGVWPFVSVDGNPISDGVPGPVTQSIIRRYWELNVEPSQLLTPVQY(SEQ ID NO:1).
[0028] In this article, the terms "starting (type) enzyme", "initial (type) enzyme" and "starting enzyme" have the same meaning, and all refer to the transaminase with the amino acid sequence of SEQ ID NO:1.
[0029] After environmental pressure combined with genetic engineering mutation, a relatively ideal mutant SEQ ID NO: 3 was finally screened out, which is a mutant in which the alanine at the 35th position of the starter enzyme is mutated to asparagine (A35N), the glutamate at the 120th position is mutated to aspartic acid (E120D), the valine at the 152th position is mutated to isoleucine (V152I), the glutamine at the 155th position is mutated to valine (Q155V), and the threonine at the 156th position is mutated to serine (T156S).
[0030] Sometimes for the sake of convenience, the starting enzyme and its mutants such as SEQ ID NO: 3 may be collectively referred to as "transaminase" herein.
[0031] The amino acid number of the aminotransferase mutant SEQ ID NO: 3 of the present invention is 330, and the structure is clear, so those skilled in the art can easily obtain its encoding gene, expression cassettes and plasmids containing these genes, and transformants containing the plasmids. These genes, expression cassettes, plasmids, and transformants can be obtained by genetic engineering construction methods well known to those skilled in the art.
[0032] In order to optimally express transaminase in the most commonly used Escherichia coli in genetic engineering, the expression genes of these enzymes can be codon optimized. Codon optimization is a technology that can be used to maximize protein expression in organisms by increasing the translation efficiency of the gene of interest. Different organisms usually show the special preference for one of some codons of the same amino acid being encoded due to mutation tendency and natural selection. For example, in fast-growing microorganisms such as Escherichia coli, the optimization codon reflects the composition of its respective genome tRNA library. Therefore, in fast-growing microorganisms, the low-frequency codons of amino acids can be replaced with codons for the same amino acids but with high frequency. Therefore, the expression of the optimized DNA sequence is improved in fast-growing microorganisms.
[0033] For example, to express a transaminase in E. coli, the gene encoding the codon-optimized starting transaminase SEQ ID NO: 1 can be SEQ ID NO: 2; and the gene encoding the transaminase mutant SEQ ID NO: 3 can be SEQ ID NO: 4.
[0034] The above-mentioned transformant host can be any microorganism suitable for expressing transaminase, including bacteria and fungi. Preferably, the microorganism is Bacillus subtilis, Corynebacterium glutamicum, Pichia pastoris, Saccharomyces cerevisiae, or Escherichia coli, preferably Escherichia coli, more preferably Escherichia coli BL21 (DE3).
[0035] When used as a biocatalyst for the production of sitagliptin, the transaminase of the present invention can be in the form of an enzyme or a bacterial cell. The enzyme forms include free enzymes, immobilized enzymes, including purified enzymes, crude enzymes, fermentation broths, enzymes fixed on carriers, etc.; the bacterial cells include living bacterial cells, dead bacterial cells, immobilized bacterial cells, etc.
[0036] When microorganisms such as Bacillus subtilis, Corynebacterium glutamicum, Pichia pastoris, Saccharomyces cerevisiae or Escherichia coli are no longer fermented and proliferated, but used for enzyme catalysis, they are themselves a natural immobilized enzyme, and do not need to be crushed or even extracted and purified, and can be used as an enzyme preparation for catalytic reactions. Since both the reaction substrate and the reaction product are small molecules, they can easily pass through the biological barrier of the bacteria - the cell membrane, so there is no need to crush the bacteria, which is economically beneficial.
[0037] The present invention is further described in detail below in conjunction with specific examples. It should be understood that the following examples are only used to illustrate the present invention and are not used to limit the scope of the present invention.
[0038] Example
[0039] This article involves the addition amount, content and concentration of various substances, and the percentages mentioned here refer to the mass percentages unless otherwise specified.
[0040] Materials and methods
[0041] The whole gene synthesis, primer synthesis and sequencing in the examples were all completed by Suzhou Genewise Biotechnology Co., Ltd.
[0042] The molecular biology experiments in the embodiments include plasmid construction, enzyme digestion, ligation, competent cell preparation, transformation, culture medium preparation, etc., and are mainly carried out with reference to Molecular Cloning Experiment Guide (3rd edition), edited by J. Sambrook and DW Russell (USA), translated by Huang Peitang et al., Science Press, Beijing, 2002). If necessary, the specific experimental conditions can be determined by simple experiments.
[0043] PCR amplification experiments were performed according to the reaction conditions provided by the plasmid or DNA template supplier or the kit instructions. If necessary, adjustments could be made through simple experiments.
[0044] LB medium: 10g / L tryptone, 5g / L yeast extract, 10g / L sodium chloride, pH 7.2. (LB solid medium plus 20g / L agar powder.)
[0045] TB medium: 24g / L yeast extract, 12g / L tryptone, 16.43g / L K 2 HPO 4 .3H 2 O, 2.31g / LKH 2 PO 4 , 5g / L glycerol, pH7.0-7.5. (TB solid medium plus 20g / L agar powder.)
[0046] HPLC detection of substrate and product chromatographic conditions: chromatographic column C18 (4.6×250mm, 5μm); mobile phase A is 50mM potassium dihydrogen phosphate solution (pH3.00), mobile phase B is acetonitrile, mobile phase A: mobile phase B = 1:1; flow rate is 1.0mL / min; detection wavelength is 254nm.
[0047] HPLC chiral detection chromatographic conditions: chromatographic column CHIRALPAK AD-H (4.6×250 mm, 5 μm); mobile phase n-hexane:ethanol:triethylamine (40:60:0.1); flow rate 0.7 mL / min, detection wavelength 268 nm.
[0048] It should be noted that, for the sake of convenience of description, in the embodiments, the strain number, plasmid number, enzyme number, and enzyme encoding gene number may share one number, which is easily understood by those skilled in the art, that is, the same number can refer to different biological forms in different environments.
[0049] Example 1: Construction of initial transaminase gene recombinant Escherichia coli
[0050] Referring to the method of Example 1 in patent document 202111141071X, based on the amino acid sequence SEQID NO: 1 of the initial enzyme ATA55, codon optimization was performed according to the codon preference of Escherichia coli, and Suzhou Jinweizhi Biotechnology Co., Ltd. was commissioned to synthesize its encoding gene SEQ ID NO: 2, and cloned into the NcoI and BamHI sites of plasmid pET28a to obtain plasmid pET-AT55.
[0051] The recombinant plasmid pET-AT55 was transformed into the expression host Escherichia coli BL21 (DE3) by electroporation to obtain the recombinant Escherichia coli EcAT55 expressing the initial aminotransferase.
[0052] Alternatively, the strain EcATA55 in Example 9 of patent document 202111141071X can be directly used for the experiment.
[0053] Example 2: Construction of the first and second round random mutation point libraries and high-throughput screening in methanol environment
[0054] 1. Construction of random mutation point library by error-prone PCR
[0055] The random mutant library was constructed using error-prone PCR technology with plasmid pET-AT55 as template.
[0056] Design the following primer pair AT-5 / AT-3:
[0057] Forward primer AT-5: 5'-CTTTAAGAAGGAGATATACCATG-3',
[0058] Reverse primer AT-3: 5′-GAGCTCGAATTCGGATCCTTA-3′.
[0059] Using plasmid pET-AT55 as a template, PCR amplification was performed to obtain a transaminase mutant DNA sequence of approximately 1.0 kb.
[0060] 50 μL error-prone PCR reaction system includes: 10 ng plasmid (pET-AT55) template, 50 pmol primer pair AT-5 and AT-3, 1× Taq buffer, 0.2 mM dGTP, 0.2 mM dATP, 1 mM dCTP, 1 mM dTTP, 7 mM MgCl 2 , (0mM, 0.05mM, 0.1mM, 0.15mM, 0.2mM)MnCl 2 , 2.5 units of Taq enzyme (Takara).
[0061] The PCR reaction conditions were: 95°C for 5 min; 94°C for 30 s, 55°C for 30 s, 72°C for 2 min / kbp, 30 cycles; 72°C for 10 min.
[0062] The PCR product was electrophoresed and recovered by gel (Axygen DNA gel recovery kit AP-GX-50). Using plasmid pET-AT55 as template and the recovered product of about 1.0 kb (random mutation fragment) as large primer, MegaPrimer PCR was performed with KOD-plus DNA polymerase: 94℃5min; 98℃10s, 60℃30s, 68℃2min / kb, 25 cycles; 68℃10min. The plasmid template was digested with DpnI restriction endonuclease (Thermo Company) and electroporated into E. coli BL21 (DE3), and more than 10 4 A random mutation library of 10 clones.
[0063] 2. High-throughput screening of mutant libraries in methanol environment
[0064] Pick a single colony to a 96-well plate (each well contains 110 μL of liquid LB-Kan medium), incubate at 37°C and 400 rpm for 5 hours, then take out 60 μL of bacterial solution from each well to a 96-well deep-well plate (each well contains 240 μL of liquid TB-Kan-0.2 mM IPTG), and incubate at 25°C and 400 rpm for 12 to 16 hours. Centrifuge at 4°C and 4000 rpm for 10 minutes to collect the bacteria, and remove the supernatant culture medium. Subsequently, wash the bacteria with pre-cooled saline, centrifuge at 4°C and 4000 rpm for 10 minutes to collect the bacteria, and remove the supernatant. Add 200 μL of enzyme reaction solution (70 mM triethanolamine, 70 mM o-phenylenediamine dihydrochloride, 0.5 g / L pyridoxal phosphate, 5 g / L compound I (sitagliptin precursor ketone), 30% methanol to each well, adjust the pH to 8.5 for reaction. Resuspend the cells, incubate at 45°C, 250 rpm for 1 to 5 h, and detect the wavelength value of 475 nm.
[0065] Select strains with significantly improved activity for nucleic acid sequencing to determine the amino acid mutation sites. At the same time, HPLC is used to detect the ee values of the reaction products of these strains. The strains with product ee values greater than 99.95% and the highest improvement in enzyme activity are selected as the starting strains for the next round of random mutant library construction. Suzhou Jinweizhi Biotechnology Co., Ltd. was commissioned to perform genome sequencing and comparison on the strains with the highest enzyme activity to determine the changes in their amino acid sequences. Repeat the establishment of the random mutation library and the high-throughput screening of the reaction system with compound I as the substrate and methanol as the solubilizer. The screening results are shown in Table 1.
[0066] Table 1. Results of high-throughput screening of random mutation libraries from round 1 to round 2
[0067]
[0068]
[0069] Note: “+” represents that the difference between the absorbance value and the starting strain reaction value is greater than 0 and less than 0.05; “++” represents that the difference between the absorbance value and the starting strain reaction value is greater than 0.05 and less than 0.1; “+++” represents that the difference between the absorbance value and the starting strain reaction value is greater than 0.1 and less than 0.2.
[0070] The ATA59 expression strain EcAT59 with the highest enzyme activity was screened out from the mutant library for the next experiment.
[0071] Example 3: Construction of random mutation point library from round 3 to round 4 and high-throughput screening under higher methanol concentration
[0072] 1. Construction of random mutation point library by error-prone PCR
[0073] Based on the amino acid sequence of the transaminase mutant ATA59, the plasmid pET-AT59 and the recombinant Escherichia coli EcAT59 expressing the mutant ATA59 were constructed according to the method of Example 1; and the random mutation point library of the transaminase ATA59 was constructed according to the method of Step 1 of Example 2.
[0074] 2. High-throughput screening of mutant libraries
[0075] Pick a single colony to a 96-well plate (each well contains 110 μL of liquid LB-Kan medium), incubate at 37°C and 400 rpm for 5 hours, then take out 60 μL of bacterial solution from each well to a 96-well deep-well plate (each well contains 240 μL of liquid TB-Kan-0.2 mM IPTG), and incubate at 25°C and 400 rpm for 12 to 16 hours. Centrifuge at 4°C and 4000 rpm for 10 minutes to collect the bacteria, and remove the supernatant culture medium. Subsequently, wash the bacteria with pre-cooled saline, centrifuge at 4°C and 4000 rpm for 10 minutes to collect the bacteria, and remove the supernatant. Add 200 μL of enzyme reaction solution (70 mM triethanolamine, 70 mM o-phenylenediamine dihydrochloride, 0.5 g / L pyridoxal phosphate, 20 g / L compound I, 50% methanol) to each well, adjust the pH to 8.5 for reaction. Resuspend the cells, incubate at 45°C, 250 rpm for 5 hours, and detect the wavelength value of 475 nm.
[0076] 3. Select strains with significantly improved activity for nucleic acid sequencing to determine the amino acid mutation sites, and detect the ee values of the reaction products of these strains by HPLC. Select strains with product ee values greater than 99.95% and the highest enzyme activity as the starting strains for the next round of random mutant library construction, and repeat the random mutation library construction and high-throughput screening with compound I as substrate and methanol as solubilization reaction system. The screening results are shown in Table 2.
[0077] Table 2. Results of high-throughput screening of random mutation libraries from round 3 to round 4
[0078]
[0079]
[0080] Note: "+" represents that the percentage of activity is greater than 0% and less than or equal to 50% relative to the respective starting strain; "++" represents that the percentage of activity is greater than 50% and less than or equal to 100% relative to the respective starting strain; "+++" represents that the percentage of activity is greater than 100% and less than or equal to 200% relative to the respective starting strain; "++++" represents that the percentage of activity is greater than 200% relative to the respective starting strain.
[0081] As can be seen from Table 2, the enzyme activity of strain EcAT64 is relatively the highest, and the amino acid sequence of the transaminase mutant ATA64 expressed by it is SEQ ID NO: 3, and the corresponding nucleic acid sequence of the encoding gene is SEQ ID NO: 4.
[0082] Example 4: Use of transaminase mutant ATA64 in the synthesis of sitagliptin
[0083] In a 1L reaction system, EcAT64 whole cells were used to catalyze the asymmetric synthesis of sitagliptin (compound II) from sitagliptin precursor ketone (compound I). The total reaction system included: 100mM triethanolamine, 1M isopropylamine, 0.5g / L pyridoxal phosphate, 100g / L compound I, 25g cells (wet weight), and 50% methanol. 100g of compound I was dissolved in methanol and added to the reaction system at a flow rate of 1mL / min. The pH value of the reaction system was controlled at about 8.5 using hydrochloric acid or isopropylamine. The reaction was completed in 8-12h.
[0084] HPLC test results show that after 12 hours of reaction, the product molar yield exceeds 97% and the product ee value is greater than 99.95%. Under the same conditions, the initial enzyme ATA55 expression strain EcAT55 whole cells catalyze the asymmetric synthesis of sitagliptin from the precursor ketone, and the product molar yield is only about 20%. This experiment proves that the transaminase mutant ATA64 is not inhibited by methanol, and to a certain extent proves that the enzyme activity of the transaminase mutant ATA64 is higher than that of the initial enzyme ATA55.
[0085] Example 5: Organic solvent adaptability of transaminase mutant ATA64
[0086] According to the method of Example 4, the reaction system of synthesizing sitagliptin by the reaction of sitagliptin precursor ketone catalyzed by EcAT64 whole cells was investigated. Unlike Example 4, other organic solvents that can form a mixed solution system with water, including DMSO and other cheap alcohols, are used in the reaction system except methanol. The experiment found that the reaction speed of EcAT64 whole cells in the reaction system using DMSO, ethanol, propanol, and isopropanol is basically the same, with little difference, indicating that DMSO, methanol, ethanol, propanol, and isopropanol have no inhibitory or low inhibitory effects on the transaminase mutant ATA64, suggesting that the transaminase mutant ATA64 is suitable for reaction systems containing these organic solvents as cosolvents. In addition, the comparative experiment also found that alcohols such as methanol, ethanol, propanol, isopropanol, etc. have considerable inhibitory effects on the initial enzyme ATA55.
[0087] In summary, the present invention screened out a mutant SEQ ID NO: 3 with wider adaptability to organic solvents and higher enzyme activity after multiple rounds of mutation under the environmental pressure of methanol as an organic co-solvent, laying a foundation for the industrialization of the enzymatic production of sitagliptin. Sequence Listing <110> Shanghai Banglin Biotechnology Co., Ltd. <120> A transaminase mutant and its application <130> SHPI2110521 <160> 4 <170> SIPOSequenceListing 1.0 <210> 1 <211> 330 <212> PRT <213> Artificial Sequence() <400> 1 Met Ala Lys Ser Ala Asp Thr Pro Ser Asn Met Tyr Thr His Asp Thr 1 5 10 15 Gly Leu Asp Tyr Ile Lys Phe Ser Glu Tyr Glu Gly Ser Ala Asp Asn 20 25 30 Asn Leu Ala Gly Gly Ala Ala Trp Ile Glu Gly Ala Phe Val Pro Pro 35 40 45 Ser Glu Ala Arg Ile Ser Val Phe Asp Gln Gly Phe Tyr Thr Ser Asp 50 55 60 Ala Thr Tyr Thr Thr Phe Ser Val Trp His Gly Asn Ala Phe Arg Leu 65 70 75 80 Asp Asp His Ile Glu Arg Leu Tyr Ser Asn Ala Glu Ser Met Arg Leu 85 90 95 Ile Pro Pro Leu Thr Gln Asp Glu Val Lys Glu Ile Ala Leu Glu Leu 100 105 110 Val Ala Lys Thr Glu Leu Arg Glu Ala Met Val Thr Val Thr Phe Thr 115 120 125 Arg Gly Leu Ser Ser Thr Pro Phe Glu Arg Asp Ile Thr Asn His Arg 130 135 140 Pro Gln Val Tyr Met Thr Ala Val Pro Tyr Gln Thr Ile Val Pro Phe 145 150 155 160 Asp Arg Ile Arg Asn Gly Val His Ala Met Val Ala Gln Ser Val Arg 165 170 175 Arg Thr Pro Arg Ser Ser Ile Asp Pro Gln Val Lys Asn Phe Gln Trp 180 185 190 Gly Asp Leu Ile Arg Ala Ile Gln Glu Thr Asn Asp Arg Gly Phe Glu 195 200 205 Leu Pro Val Leu Leu Asp Cys Asp Gly Leu Leu Ala Glu Gly Pro Gly 210 215 220 Phe Asn Val Val Val Ile Lys Asp Gly Val Val Arg Ser Pro Gly Arg 225 230 235 240 Ala Ala Leu Pro Gly Ile Thr Arg Lys Thr Val Leu Glu Ile Ala Glu 245 250 255 Ser Leu Gly His Glu Ala Ile Leu Ala Asp Ile Ser Leu Ala Asp Leu 260 265 270 Tyr Asp Ala Asp Glu Val Leu Gly Cys Ser Thr Gly Gly Gly Val Trp 275 280 285 Pro Phe Val Ser Val Asp Gly Asn Pro Ile Ser Asp Gly Val Pro Gly 290 295 300 Pro Val Thr Gln Ser Ile Ile Arg Arg Tyr Trp Glu Leu Asn Val Glu 305 310 315 320 Pro Ser Gln Leu Leu Thr Pro Val Gln Tyr 325 330 <210> 2 <211> 990 <212> DNA <213> Artificial Sequence () <400> 2 atggcaaaaa gtgctgatac accctcaaat atgtatacgc atgataccgg tcttgactac 60 atcaagttca gcgagtacga aggtagcgca gacaacaacc tggctggtgg cgcggcatgg 120 attgaaggcg cgttcgtgcc accgtccgag gcgcgtatct ccgtctttga ccagggtttt 180 tacaccagcg acgcgaccta tactacgttt agtgtgtggc acggcaacgc gttccgcttg 240 gacgaccaca tcgagcgttt gtacagcaat gcggagagca tgcgtctgat tccgccgctg 300 acccaagatg aggtgaaaga aatcgctctg gaattggttg cgaaaacgga actgcgtgaa 360 gctatggtta cggtgacctt tacccgtgga ttaagctcga ccccgttcga gcgcgatatc 420 acgaaccatc gaccgcaagt ttatatgacc gcagttccgt atcagaccat tgtcccattc 480 gatcgcatcc gcaatggtgt gcacgcgatg gtggcacagt ctgtgcgtcg taccccgcgt 540 agcagcattg atccgcaagt gaagaacttt cagtggggtg atctgattag agccatccaa 600 gagaccaacg atcgtggttt cgaacttccg gttctgctgg actgtgatgg tttactggct 660 gagggccctg gcttcaacgt tgtggttatt aaggacggcg tcgtacgctc tccgggccgt 720 gcggcactgc cgggtattac ccgtaaaacc gttctggaga tcgcggagtc gctgggtcat 780 gaagccatcc tggcggacat ttctttggct gacctctacg atgcggacga ggttctgggc 840 tgcagcactg gtggcggtgt ttggccattt gttagcgtcg atggtaatcc gatttccgac 900 ggcgtcccgg gtccggtaac acaaagcatc atccgccgtt actgggaatt gaatgtggaa 960 ccgtcccagc tgttgacccc ggtgcagtat 990 <210> 3 <211> 330 <212> PRT <213> Artificial Sequence () <400> 3 Met Ala Lys Ser Ala Asp Thr Pro Ser Asn Met Tyr Thr His Asp Thr 1 5 10 15 Gly Leu Asp Tyr Ile Lys Phe Ser Glu Tyr Glu Gly Ser Ala Asp Asn 20 25 30 Asn Leu Asn Gly Gly Ala Ala Trp Ile Glu Gly Ala Phe Val Pro Pro 35 40 45 Ser Glu Ala Arg Ile Ser Val Phe Asp Gln Gly Phe Tyr Thr Ser Asp 50 55 60 Ala Thr Tyr Thr Thr Phe Ser Val Trp His Gly Asn Ala Phe Arg Leu 65 70 75 80 Asp Asp His Ile Glu Arg Leu Tyr Ser Asn Ala Glu Ser Met Arg Leu 85 90 95 Ile Pro Pro Leu Thr Gln Asp Glu Val Lys Glu Ile Ala Leu Glu Leu 100 105 110 Val Ala Lys Thr Glu Leu Arg Asp Ala Met Val Thr Val Thr Phe Thr 115 120 125 Arg Gly Leu Ser Ser Thr Pro Phe Glu Arg Asp Ile Thr Asn His Arg 130 135 140 Pro Gln Val Tyr Met Thr Ala Ile Pro Tyr Val Ser Ile Val Pro Phe 145 150 155 160 Asp Arg Ile Arg Asn Gly Val His Ala Met Val Ala Gln Ser Val Arg 165 170 175 Arg Thr Pro Arg Ser Ser Ile Asp Pro Gln Val Lys Asn Phe Gln Trp 180 185 190 Gly Asp Leu Ile Arg Ala Ile Gln Glu Thr Asn Asp Arg Gly Phe Glu 195 200 205 Leu Pro Val Leu Leu Asp Cys Asp Gly Leu Leu Ala Glu Gly Pro Gly 210 215 220 Phe Asn Val Val Val Ile Lys Asp Gly Val Val Arg Ser Pro Gly Arg 225 230 235 240 Ala Ala Leu Pro Gly Ile Thr Arg Lys Thr Val Leu Glu Ile Ala Glu 245 250 255 Ser Leu Gly His Glu Ala Ile Leu Ala Asp Ile Ser Leu Ala Asp Leu 260 265 270 Tyr Asp Ala Asp Glu Val Leu Gly Cys Ser Thr Gly Gly Gly Val Trp 275 280 285 Pro Phe Val Ser Val Asp Gly Asn Pro Ile Ser Asp Gly Val Pro Gly 290 295 300 Pro Val Thr Gln Ser Ile Ile Arg Arg Tyr Trp Glu Leu Asn Val Glu 305 310 315 320 Pro Ser Gln Leu Leu Thr Pro Val Gln Tyr 325 330 <210> 4 <211> 990 <212> DNA <213> Artificial Sequence () <400> 4 atggcaaaaa gtgctgatac accctcaaat atgtatacgc atgataccgg tcttgactac 60 atcaagttca gcgagtacga aggtagcgca gacaacaacc tgaatggtgg cgcggcatgg 120 attgaaggcg cgttcgtgcc accgtccgag gcgcgtatct ccgtctttga ccagggtttt 180 tacaccagcg acgcgaccta tactacgttt agtgtgtggc acggcaacgc gttccgcttg 240 gacgaccaca tcgagcgttt gtacagcaat gcggagagca tgcgtctgat tccgccgctg 300 acccaagatg aggtgaaaga aatcgctctg gaattggttg cgaaaacgga actgcgtgat 360 gctatggtta cggtgacctt tacccgtgga ttaagctcga ccccgttcga gcgcgatatc 420 acgaaccatc gaccgcaagt ttatatgacc gcaattccgt atgtgtccat tgtcccattc 480 gatcgcatcc gcaatggtgt gcacgcgatg gtggcacagt ctgtgcgtcg taccccgcgt 540 agcagcattg atccgcaagt gaagaacttt cagtggggtg atctgattag agccatccaa 600 gagaccaacg atcgtggttt cgaacttccg gttctgctgg actgtgatgg tttactggct 660 gagggccctg gcttcaacgt tgtggttatt aaggacggcg tcgtacgctc tccgggccgt 720 gcggcactgc cgggtattac ccgtaaaacc gttctggaga tcgcggagtc gctgggtcat 780 gaagccatcc tggcggacat ttctttggct gacctctacg atgcggacga ggttctgggc 840 tgcagcactg gtggcggtgt ttggccattt gttagcgtcg atggtaatcc gatttccgac 900 ggcgtcccgg gtccggtaac acaaagcatc atccgccgtt actgggaatt gaatgtggaa 960 ccgtcccagc tgttgacccc ggtgcagtat 990
Claims
1. A transaminase mutant, It is characterized in that The amino acid sequence is SEQ ID NO:
3.
2. A gene encoding the transaminase mutant according to claim 1.
3. The gene according to claim 2, It is characterized in that The nucleotide sequence is SEQ ID NO:
4.
4. A plasmid comprising the gene as claimed in claim 3.
5. A microorganism for expressing the aminotransferase mutant according to claim 1, It is characterized in that A microorganism transformed with the plasmid as claimed in claim 4.
6. The microorganism according to claim 5, It is characterized in that The microorganism is selected from Bacillus subtilis, Pichia pastoris, Saccharomyces cerevisiae and Escherichia coli.
7. The microorganism according to claim 6, It is characterized in that The microorganism is Escherichia coli BL21 (DE3).
8. Use of the transaminase mutant according to claim 1 or the microorganism according to claim 5 in producing sitagliptin.
9. The use according to claim 8, It is characterized in that Sitagliptin is obtained by using (2Z)-4-oxo-4-[3-(trifluoromethyl)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazine-7-(8H)-yl]-1-(2,4,5-trifluorophenyl)butan-2-one as a reaction substrate and using the aminotransferase mutant according to claim 1 or the microorganism according to claim 5 to catalyze the amino transfer reaction.
10. The use according to claim 9, It is characterized in that The reaction system contains pyridoxal phosphate as a coenzyme.
11. The use according to claim 9, It is characterized in that The reaction system also contains o-phenylenediamine dihydrochloride, isopropylamine or triethanolamine as an amino donor.
Citation Information
Cited By
Method for constructing D-p-hydroxyphenylglycine producing strain
CN119410680A
